CKM-PREVCardiovascular-Kidney-Metabolic Syndrome Prevalence and Risk Factors in Gaziantep, Turkey
Data Collection
Collected at a single point in time - Cross-sectionalUrogenital Diseases+16
+ Cardiovascular Diseases
+ Chronic Disease
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: June 1, 2025
Actual date on which the first participant was enrolled.This study is focused on understanding the prevalence of Cardiovascular-Kidney-Metabolic (CKM) Syndrome in a community in Gaziantep, Türkiye. CKM Syndrome is a newly defined condition that involves a combination of cardiovascular diseases, diabetes, and chronic kidney diseases, which are major health concerns in Turkey and worldwide. The American Heart Association (AHA) has classified CKM Syndrome into stages ranging from 0 to 4, based on risk factors and disease presence. This research aims to provide the first set of community-based data in Türkiye regarding these stages. It also seeks to explore how these stages relate to the SCORE-2 risk score, which predicts cardiovascular risk, and the Body Roundness Index (BRI), which measures abdominal obesity. The findings could aid local healthcare practices by offering insights into the management and screening of CKM Syndrome. Participants in this study are individuals aged 30 to 79 years who are registered at the Bağlarbaşı Family Health Center in Gaziantep. The study will use existing medical records and biochemical test results to classify participants into CKM stages. Anthropometric measurements, such as weight, height, and waist circumference, will be taken on-site to calculate indices like BMI and BRI. The study will use the SCORE-2 calculator to estimate participants' 10-year risk of cardiovascular problems, considering factors such as age, sex, blood pressure, and cholesterol levels. By evaluating these measurements and risks, the research aims to identify correlations that can help in understanding and managing CKM Syndrome more effectively.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.400 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 30 to 79 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Age between 30 and 79 years Residence in Gaziantep, Türkiye Availability of the following laboratory tests performed within the past 1 month: Fasting glucose HbA1c Lipid profile (total cholesterol, LDL, HDL, triglycerides) Creatinine Estimated glomerular filtration rate (eGFR) Ability to provide informed consent Exclusion Criteria Presence of severe physical or mental disability Hospitalization due to acute illness within the past 3 months Pregnancy
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Bağlarbaşı Family Health Center
Gaziantep, Turkey (Türkiye)Open Bağlarbaşı Family Health Center in Google Maps